Abstract: Poster Presentations |


Raymond Klein, MD*
Author and Funding Information

ZLB Behring, King of Prussia, PA

Chest. 2006;130(4_MeetingAbstracts):183S. doi:10.1378/chest.130.4_MeetingAbstracts.183S-b
Text Size: A A A
Published online


PURPOSE: To investigate patient satisfaction with augmentation therapy.

METHODS: A questionnaire (taking 30 minutes to complete) was mailed to patients (n=66) with alpha1-antitrypsin deficiency (AATD) who were receiving Zemaira® (ZLB Behring, Philadelphia, USA) [Z(A1-PI)] in the United States. The survey determined: which products patients had used for AATD; the patient’s role in product selection; product attributes; and level of satisfaction/dissatisfaction with key attributes of Z(A1-PI) compared with other augmentation therapies.

RESULTS: Fifty-seven patients (51% male; age 36-75 years) returned the questionnaire. Thirty patients were new to augmentation therapy and 27 had switched from an alternative therapy (Prolastin® [P(A1-PI)]; Talecris Biotherapeutics Inc., North Carolina, USA; Aralast™ [A(A1-PI)]; Baxter Healthcare Corporation, Illinois, USA); average duration of Z(A1-PI) use was 10.4 months. Patients cited physician’s recommendation (61%), shorter infusion time (39%), and product purity (33%) as the main reasons for selecting Z(A1-PI). The main reasons for switching to Z(A1-PI) were shorter infusion time (52%) and product purity (48%). Reducing the rate of lung function decline was the most important attribute of AATD therapy. The infusion and reconstitution time for Z(A1-PI) was nearly half that for the other augmentation therapies (infusion time: 33.8 mins vs 64.4 mins; reconstitution time: 13.6 mins vs 29.0 mins; both p≤0.05). Adverse events were reported by 30% and 59% of patients receiving Z(A1-PI) and P(A1-PI)/A(A1-PI), respectively (p≤0.05). On a scale of 1 to 5 (1 = not at all satisfied; 5 = extremely satisfied), 83% of patients rated their satisfaction with Z(A1-PI) as 4 or 5. Feeling better/improved quality of life (32%), shorter infusion time (22%) and no adverse events (21%) were the main reasons for the ratings.

CONCLUSION: Reducing the rate of lung function decline, short infusion time and higher product purity were important attributes in patients with AATD receiving Z(A1-PI). Improved quality of life was the main reason for high satisfaction with Z(A1-PI).

CLINICAL IMPLICATIONS: Patients’ views and product attributes should be considered when selecting alpha1-antitrypsin therapy.

DISCLOSURE: Raymond Klein, Employee RK is an employee of ZLB Behring; Other The research was funded by ZLB Behring.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543